Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations
Authors
Keywords
-
Journal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-05
DOI
10.1007/s10928-023-09896-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Streamlining Food Effect Assessment — Are Repeated Food Effect Studies Needed? An IQ Analysis
- (2023) Filippos Kesisoglou et al. AAPS Journal
- Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs
- (2023) Yan Ji et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Backfilling cohorts in phase I dose-escalation studies
- (2023) Helen Barnett et al. Clinical Trials
- Practical recommendations for using ctDNA in clinical decision making
- (2023) Stacey A. Cohen et al. NATURE
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
- (2023) Valsamo Anagnostou et al. NATURE MEDICINE
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug–Disease Interaction Under Different Clinical Conditions
- (2022) Milo Gatti et al. CLINICAL PHARMACOKINETICS
- Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
- (2022) Jeanne Fourie Zirkelbach et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
- (2022) Suzette Girgis et al. Blood Advances
- Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure–response relationships for large‐molecule oncology drugs
- (2022) Victor Poon et al. CPT-Pharmacometrics & Systems Pharmacology
- Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases
- (2022) Hisham Qosa et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Immunogenicity Considerations for Therapeutic Modalities Used in Rare Diseases
- (2022) Anas M. Fathallah et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Pharmacology in Drug Development for Rare Diseases in Neurology: Contributions and Opportunities
- (2021) Bilal Abuasal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations
- (2021) Derek Z. Yang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Drug-Dosing Conundrum in Oncology — When Less Is More
- (2021) Mirat Shah et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expanding cancer predisposition genes with ultra-rare cancer-exclusive human variations
- (2020) Roni Rasnic et al. Scientific Reports
- Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
- (2016) Y. Yuan et al. CLINICAL CANCER RESEARCH
- Rare cancers: a sea of opportunity
- (2016) Niki Boyd et al. LANCET ONCOLOGY
- Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper
- (2014) P. G. Casali et al. ANNALS OF ONCOLOGY
- Oral Chemotherapy Food and Drug Interactions: A Comprehensive Review of the Literature
- (2014) Eve M. Segal et al. Journal of Oncology Practice
- Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
- (2012) Christophe Le Tourneau et al. PLoS One
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More